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ABSTRACT 
 
OBJECTIVE: The objective of this selective evidence based medicine review is to determine 
whether or not oral gabapentin administered prior to scheduled cesarean delivery decreases pain 
with movement in adult women at 24 hours postpartum as compared to placebo. DESIGN: 
Review of three English language, peer-reviewed, primary studies published after 2000. 
SOURCES: Three randomized, placebo-controlled trials comparing the efficacy of oral 
gabapentin to a lactose placebo in adult women undergoing elective cesarean delivery. Sources 
were selected from PubMed, Medline, Ovid, and the Cochrane Database to include all studies 
matching the keywords that were published in peer-reviewed, English language journals after 
2000 and included only women over 18 years of age. OUTCOMES MEASURED: Primary 
outcome measured was patient reported pain perception on a 0-100mm Visual Analog Scale 
(VAS - 0 = no pain, 100 = worst possible pain) measured 24 hours post cesarean section. 
Satisfaction with pain management, as measured by a numerical rating scale (0-10) was 
considered secondarily. RESULTS: Two of the three studies found significant improvement in 
post-cesarean delivery analgesia and satisfaction with analgesia with adjunctive gabapentin 
therapy at doses of 600mg and 300mg respectively. A third study investigated both dosages, but 
found no clinical benefit to either. CONCLUSIONS:  Evidence is inconclusive as to whether oral 
gabapentin administered prior to scheduled cesarean delivery decreases pain with movement in 
adult women at 24 hours postpartum as compared to placebo. 
KEY WORDS: Gabapentin, Pregnancy, Cesarean Section, Cesarean Delivery. 
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INTRODUCTION 
Cesarean delivery is the most commonly performed surgical procedure in the United 
States and accounts for roughly 30% of all deliveries.1 While traditionally indicated for high-risk 
pregnancies in which vaginal delivery would result in increased maternal or fetal mortality, it has 
become increasingly common in recent decades as women without medical indication request the 
procedure. Estimates of prevalence for cesarean delivery by maternal request are as high as 18% 
of all deliveries worldwide and 2.5% in the United States.1,2 Patient reported reasons for elective 
cesarean delivery include convenience of scheduled delivery, fear of pain and childbirth, as well 
as poor past experiences with spontaneous vaginal delivery.2 Additionally, elective cesarean 
delivery proffers a number of medical benefits to both the mother and fetus, including decreased 
risk of pelvic floor injury, fetal shoulder dystocia, maternal-fetal transmission of herpes simplex 
virus and human immunodeficiency virus, and late-term still birth.2 
Despite the benefits, cesarean delivery also presents a number of unique risks to both 
mother and fetus. Studies indicate that patients are most concerned about intra- and post-
operative pain from cesarean delivery, and for good reason; one of the most commonly reported 
complications from cesarean delivery is pain.3 The mechanism for this is not well understood. 
Contributing factors may include unopposed central sensitization of nociceptors, neuropathic 
sensitization following nerve entrapment, and incision type.4 Access to the abdomen and uterus 
is typically gained via a Pfannenstiel-type incision, which may result in entrapment of the 
iliohypogastric and ilioinguinal nerves and chronic pelvic pain months after the procedure.4,5  
Cesarean section pain is typically managed with a combination of anesthetics and 
analgesics. Intra-operative bupivacaine is most commonly employed for spinal anesthesia, while 
lidocaine with epinephrine is most commonly employed in epidural anesthesia; both may be used 
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with adjunctive opioids or fentanyl to provide analgesia for 18-24 hours.6 Post-operative 
analgesia is typically achieved with a multimodal approach including patient-controlled IV 
morphine, non-steroidal anti-inflammatory drugs, and acetaminophen.6 
Opioid analgesia, however, poses many potential risks and may be inappropriate in 
patients who are opioid naïve, have allergies to opiates, or suffer from an opiate addiction.7,8 
Morphine products like Astramorph/PF, Infumorph, and Duramorph, carry warnings for 
overdose and resuscitation in the setting of epidural/intrathecal administration, and their use post-
operatively have been noted to negatively affect the heart rate of the fetus and result in 
respiratory depression of the breastfeeding newborn.7 These findings are supported by studies 
demonstrating a longer time to first interaction between mother and baby, longer times to breast 
feeding, decreased ability to breast feed, decreased maternal-fetal bonding, and decreased 
satisfaction with the birthing experience associated with opioid pain management following 
cesarean delivery.3,8,9  
Furthermore, chronic pain following cesarean delivery has substantial impact on the cost 
of healthcare. In 2008, cesarean delivery with complications, such as prolonged pain, resulted in 
an additional two days hospitalization over vaginal delivery (mean 4.5 days vs. 2.6 days) and 
accounted for 46% of hospital delivery costs.10 Of those deliveries with complications, it is 
estimated that 12.3% specifically result in debilitating pain that affects infant care within the first 
6 months postpartum, accounting for $3.1 billion of hospital delivery costs.10 
With the number of adverse effects and the overwhelming costs of care associated with 
chronic, debilitating pain following cesarean delivery, alternative methods of pain control are 
essential. Gabapentin, a centrally-acting calcium channel alpha 2-delta ligand used in the 
management of neuropathic pain, is a relatively safe alternative that has been shown to be 
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effective in decreasing acute post-surgical pain in similar procedures, such as total 
hysterectomy.8 Although classified as pregnancy category C, studies have yet to demonstrate 
increased maternal-fetal risk from gabapentin exposure within hours of delivery. Gabapentin is 
excreted in breast milk at a rate of 1 mg/kg/day; the effect that this has on newborns is 
unknown.7  
 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not oral gabapentin 
administered prior to scheduled cesarean delivery decreases pain with movement in adult women 
at 24 hours postpartum as compared to placebo. 
 
METHODS 
Three studies were included in the analysis. All studies were randomized, double-blind, 
placebo-controlled trials investigating the efficacy of oral gabapentin administered prior to 
delivery compared to a visually-matched, lactose placebo in adult women undergoing elective 
cesarean delivery. The primary outcome measured was pain with movement at 24 hours post-
operation. Studies also measures satisfaction with pain management. 8,11,12    
 Sources were queried from PubMed, Medline, Cochrane Database, and OVID to include 
English-language studies of adult women in peer-reviewed journals published after 2000. 
Articles were selected by the author based on their relevance to the clinical question. Articles 
were excluded if they were published outside of the search window, were not published in a 
peer-reviewed publication, were not in English, or included women younger than 18 years of 
age. Additionally, articles were excluded if they had appeared in prior meta-analyses or 
Boller, Gabapentin for Cesarean Delivery – 4 
systematic reviews of similar clinical inquiries. Key words included gabapentin, pregnancy, 
cesarean delivery, and cesarean section.  
 
OUTCOMES MEASURED  
The primary outcome for all three studies was patient reported pain perception with 
movement as measured by a 0-100mm Visual Analog Scale (VAS - 0 = no pain, 100 = worst 
possible pain) 24 hours post cesarean section. 8,11,12  Moore et al8  and Short et al12 further defined 
primary outcomes as VAS scores 6, 12, and 48 hours post-cesarean section with movement and 
at rest, as well as at three months post-operatively. Anaraki et al11 also defined primary outcomes 
as time to first request for supplemental analgesia and total dose of supplemental analgesia 
required.  
Secondary measures varied by study. All three studies measured patient satisfaction with 
intra- and post-operative analgesia. 8,11,12  Moore et al8 and Anaraki et al11 utilized a 0-10 
numerical rating scale (NRS). Short et al12 used a 0-100 VAS (0 = not satisfied, 100 = 
completely satisfied). Safety and tolerability were assessed by Moore et al8 and Short et al12 
using a patient reported numerical rating scale of 0-3 for level of sedation, nausea, vomiting, 
dizziness, and pruritus. Anaraki et al11 do not explicitly monitor for safety and tolerability, but 
report nursing assessments of nausea, sedation, and pruritus. 
 
RESULTS 
Study Designs and Subject Selection 
Study subjects were enrolled from either an internationally-regarded Canadian tertiary 
care hospital8,12 or a Middle-Eastern teaching hospital.11 Subjects were English-speaking women 
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over 18 years of age presenting at term for elective cesarean delivery on an inpatient basis. 
Gravity and parity were null factors in subject selection in two studies;8,12 the third excluded all 
multiparous women.11 Patients were excluded from participation if they had moderate to severe 
systemic illness as evidenced by an ASA Physical Status Score of 3 or greater; infectious 
diseases, including HIV and hepatitis; uncontrolled hypertension or diabetes mellitus; 
contraindications to neuraxial anesthesia/study medications; or had taken pain medications one 
week prior to surgery. Patients were also excluded if they were known IV drug users or were 
carrying fetuses with known congenital abnormalities. All three studies utilized a 
demographically-matched placebo-controlled group.8,11,12  
Dosing of gabapentin varied by study, with Moore et al8 dosing 600mg orally, Anaraki et 
al11 dosing 300mg orally, and Short et al12 dosing both 600mg and 300mg orally. The variable 
dosing accounts for the lack studies demonstrating replicable therapeutic levels of gabapentin for 
peri-operative pain and attempts to find the minimum necessary therapeutic dosage.6,7,12 One 
study administered gabapentin two hours pre-operatively11 and the other two studies 
administered the study drug one hour pre-operatively.8,12 Compliance was 100%, as only one 
dose was required and was administered by study staff prior to surgery. 
 Intra-operative anesthesia was managed similarly across studies and consisted of either 
0.75% bupivacaine 8,12 or 0.5% bupivacaine.11 Moore et al8 and Short et al12 augmented the 
anesthesia with 10μg fentanyl and 100μg morphine, per hospital protocol, for all subjects, 
regardless of study arm. Anaraki et al11 additionally administered 10μg fentanyl intrathecally to 
the control group only to mitigate pain. In all studies, subjects were able to request additional 
opioid analgesia post-operatively to augment pain management. 
A summary of selected studies is presented in Table 1. 
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Moore et al8  
 A total of 46 subjects were distributed evenly to each arm of the study, with two excluded 
from analysis in the gabapentin group due to unblinding and spontaneous vaginal delivery. VAS 
scores were compared using a repeated measures analysis of variance (ANOVA). Categorical 
data, such as satisfaction and adverse event severity, were analyzed by χ2, Fisher exact test, or 
Mann-Whitney U test. At 24 hours post cesarean delivery, the gabapentin group showed 
significantly less pain with movement than the placebo group, with mean VAS scores (95% CI) 
of 21mm (13-29) and 41mm (32-51), respectively (P = 0.001). Subjects in the gabapentin group 
were also significantly more satisfied with their pain management than the subjects in the 
placebo group at 24 hours (NRS, p=0.02). 5 subjects in each group requested supplemental 
morphine. There was no significant difference in the amount of supplemental morphine dosed. 
Mean total supplemental morphine (95% CI) for the gabapentin group was 4.2mg (1.1-7.2) and 
3.2mg (1.0-5.4) for the placebo group (p=0.58).  
 
Short et al 12 
A total of 132 subjects were distributed evenly to each arm of the study, with 6 excluded 
from analysis for failed spinal (3), protocol breach (2), or postponed procedure (1). VAS scores 
were compared using a repeated measures analysis of variance (ANOVA) with Bonferroni 
correction (pairwise α = 0.05 / 3 comparisons = 0.016) for multiple comparisons across the three 
treatment groups. Categorical data, such as adverse event severity and NICU admission, were 
analyzed by Fisher exact test or nonparametric Kruskal-Wallis tests.  
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At 24 hours post cesarean delivery, there were no significant differences between groups 
in pain scores with movement (overall p=0.61). Comparison of the 600mg gabapentin group to 
the 300mg gabapentin group revealed improved pain control with the lower dose that was not 
significant (mean difference = 5mm with 95% adjusted CI = -7 to 17). Comparison of 300mg to 
placebo reveals a non-significant improvement in pain control (mean difference = -2mm with 
95% adjusted CI = -14 to 10). 38 total subjects requested supplemental morphine. There was no 
significant difference in the amount of supplemental morphine dosed. Mean total supplemental 
morphine (95% CI) for the gabapentin 300mg group was 5.7mg (1.3-10.2), 6.7mg (4.7-8.8) for 
the gabapentin 600mg group, and 7.9mg (5.9-9.9) for the placebo group (p=0.46). 
 
Anaraki et al 11 
A total of 78 subjects were distributed evenly to each arm of the study, with one excluded 
from analysis in the gabapentin group due to failure of the spinal block. VAS scores, maternal 
satisfaction, and supplemental morphine usage were analyzed by χ2 or Mann-Whitney U test. At 
24 hours post cesarean delivery, the gabapentin group showed significantly less pain with 
movement than the placebo group, with mean VAS scores (95% CI) of 24mm (13-30) and 38mm 
(24-56), respectively (P = 0.001). Subjects in the gabapentin group were also significantly more 
satisfied with their pain management than the subjects in the placebo group at 24 hours (NRS 
mean (range) = 7 (4-10) gabapentin, 5 (1-9) placebo; p=0.001). Authors did not report how many 
subjects in each group required supplemental morphine; however, in those subjects who did 
receive supplemental morphine, the time to first dose was significantly longer in the gabapentin 
group compared to placebo (mean hours (SD) = 4.59 (1.63) gabapentin, 2.65 (0.92) placebo; 
p=0.000). Subjects in the gabapentin group requesting supplemental morphine also requested 
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less than the placebo group. Mean total supplemental morphine (SD) for the gabapentin group 
was 7.18mg (3.26) and 12.62mg (5.16) for the placebo group (p=0.000). 
 
Safety and Tolerability 
 A well reported side effect of gabapentin use is sedation.7,12 The selected studies provide 
further evidence for this effect. Moore et al8 demonstrate a significant difference in incidence of 
severe sedation between gabapentin and placebo groups (19% vs. 0%, p=0.04) and note that 
severe sedation occurred early, as there were no reports of sedation after 24 hours. Severe 
sedation was not correlated with VAS pain ratings or satisfaction scales, although R values are 
not reported.  
 Short et al12 refutes this claim, finding no increase in maternal sedation with either 
600mg of gabapentin or a reduced dose of 300mg. They posit that the findings of the 2011 study 
were the result of researcher bias. However, Anaraki et al11 document increased sedation at a 
dose of 300mg compared to the placebo group (p=0.012).  
 Independent analyses of the combined reported adverse events in these three studies 
supports this data (Table 2). The most deleterious adverse event encountered was nausea (NNH 
= 27.2). Comparatively, sedation was relatively mild (NNH = 488.48) and pruritus least likely 
(NNH = 767.96). 
Neonatal outcomes were similar for all participants in all studies (Table 3). 
 
DISCUSSION 
Two of the three studies found significant improvement in post-cesarean delivery 
analgesia and satisfaction with analgesia with adjunctive gabapentin therapy at doses of 600mg 
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and 300mg respectively. 8,11 Dose finding studies in other surgical situations indicate that a 
typical dose of 300-1200mg pre-operatively may be effective.12 Short et al varied the doses 
accordingly, studying both 300 and 600mg doses, but found no clinical benefit.12 
Gabapentin is capable of potentiating the effect of morphine, leading to prolonged 
analgesia and marked CNS depression.7 While the included studies demonstrated relative safety 
of the drug during labor and delivery and in the immediate postpartum period, patients must be 
counseled about, and monitored for, common side effects of gabapentin administration, including 
increased sedation, angioedema, multi-organ hypersensitivity (DRESS syndrome), and suicidal 
ideation.7 Additionally, providers should use gabapentin with caution in patients with impaired 
renal function, as gabapentin is renally-excreted.7 
 Moreover, care providers should take into consideration cost and coverage of drugs used 
during labor and delivery. The wholesale cost for the dosages of gabapentin used in the included 
studies are $252.62 per 100 tablets ($2.53/dose) for gabapentin 600mg and $133.20 per 100 
tablets ($1.33/dose). This is in adjunct to the standard opiate analgesia, which is not inexpensive 
($3.30 for 3mg epidural morphine; $0.11 for 100mcg intrathecal morphine).7  
Limitations 
Further research is warranted to address a number of issues among the studies. With a 
limited sample size, the generalizability of the results to other women requesting cesarean 
delivery is questionable. Although all three studies recorded the amount of supplemental 
morphine administered per patient request, in depth analyses of these patients as their own sub-
group were not conducted. None of the studies included women undergoing cesarean delivery on 
a non-elective or emergent basis. Future study is warranted to evaluate the effects of oral 
gabapentin in the management of these populations before routine use can be recommended. 
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CONCLUSION 
 Evidence is inconclusive as to whether oral gabapentin administered prior to scheduled 
cesarean delivery decreases pain with movement in adult women at 24 hours postpartum as 
compared to placebo.  
At the time of writing, recent publication of new data from Monks et al13 aims to clarify 
many of these issues and finds that one pre-operative dose of gabapentin followed by 6 post-
operative doses over two days produces modest improvement in pain scores and satisfaction with 
pain management over control. This improvement comes at the expense of marked sedation, 
casting the role of gabapentin in a multimodal approach to pain management for cesarean 
delivery in doubt. 
  
Boller, Gabapentin for Cesarean Delivery – 11 
Table 1 - Demographics & Characteristics of Selected Studies 
Study Type # 
pts 
Age (y) Inclusion Exclusion W/D Interventions 
Moore 
(2011) 
Double
-blind 
RCT 
46 >18y 
(mean 
= 34)  
• Full-term 
pregnant 
women 
undergoing 
scheduled 
cesarean 
delivery 
•>18 years 
• ASA Physical Status Score of ≥3 
• Contraindications to neuraxial anesthesia 
• History of HIV, hepatitis,  uncontrolled 
hypertension, or diabetes mellitus 
• Known IVDU 
• Women with fetuses having known 
congenital abnormalities 
• Women having taken pain medications 
one week prior to surgery 
2 Experimental: 600mg 
gabapentin PO 1 hour 
before surgery 
 
Control: Lactose 
placebo 
 
 
Short 
(2012) 
Double
-blind 
RCT 
132 >18y 
(mean 
= 34.8) 
• Full-term 
women with 
singleton 
pregnancies 
undergoing 
scheduled 
cesarean 
delivery 
•>18 years 
• ASA Physical Status Score of ≥3 
• Contraindications to neuraxial anesthesia 
• History of epilepsy, central nervous 
system or mental disorders, chronic pain, 
drug abuse, or use of neuropathic analgesics 
or antiepileptic drugs 
• Women with fetuses having known 
congenital abnormalities 
6 Experimental:  
- 600mg gabapentin 
PO 1 hour before 
surgery;  
- 300mg gabapentin 
PO 1 hour before 
surgery 
 
Control: Lactose 
placebo 
Anara
ki 
(2014) 
Double
-blind 
RCT 
78 >18y 
(mean 
= 27) 
•Full term, 
primiparous 
women 
undergoing 
scheduled 
cesarean 
delivery 
•>18 years 
• ASA Physical Status Score of ≥3  
• Contraindications to neuraxial anesthesia 
• History of smoking, hepatitis, chronic use 
of gabapentin or opioids, psychological 
problems, severe preeclampsia, and diabetes 
mellitus  
• Women with fetuses having known 
congenital abnormalities 
1 Experimental: 300mg 
gabapentin PO 2 hour 
before surgery 
 
Control: Lactose 
placebo PO and 10ug 
fentanyl IV 
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Table 2.  Safety and Tolerability of Gabapentin versus Lactose Placebo 
 CER (N) EER (N) RRI ARI NNH 
NAUSEA 
Cumulative 46 (107) 49 (105) 0.09 0.04 27.2 
Moore 2011† 
Short 2012, 600mg 
Short 2012, 300mg 
Anaraki 2014 
8 (23) 
19 (42) 
19 (42) 
--  
12 (21) 
19 (42) 
18 (42) 
--  
0.64‡ 
0 
-0.05 
-- 
0.22 
0 
-0.02 
-- 
4.47 
0 
-42 
-- 
VOMITING 
Cumulative 28 (145) 26 (143) -0.06 -0.01 -88.61 
Moore 2011 
Short 2012, 600mg 
Short 2012, 300mg 
Anaraki 2014 
3 (23) 
10 (42) 
10 (42) 
5 (38) 
5 (21) 
7 (42) 
10 (42) 
4 (38) 
0.83 
-0.30 
0 
-0.22 
0.11 
-0.07 
0 
-0.03 
9.29 
-14 
0 
-34.47 
SEDATION 
Cumulative 65 (107) 64 (105) 0.003 0.002 488.48 
Moore 2011 
Short 2012, 600mg 
Short 2012, 300mg 
Anaraki 2014 
17 (23) 
24 (42) 
24 (42) 
-- 
17 (21) 
23 (42) 
24 (42) 
-- 
0.10 
-0.04 
0 
-- 
0.07 
-0.02 
0 
-- 
14.21 
-42 
0 
-- 
PRURITUS 
Cumulative 86 (145) 85 (143) 0.002 0.001 767.96 
Moore 2011 
Short 2012, 600mg 
Short 2012, 300mg 
Anaraki 2014 
22 (23) 
32 (42) 
32 (42) 
0 (38) 
16 (21) 
33 (42) 
36 (42) 
0 (38) 
-0.20 
0.03 
0.13 
0 
-0.19 
0.02 
0.1 
0 
-5.14 
42 
10.5 
0 
† Moore 2011 – Gabapentin 600mg; Short 2012- Gabapentin 600mg; Anaraki 2014 – 
Gabapentin 300mg 
‡ Results rounded for simplicity of presentation. Calculations done without rounding. 
 
Table 3. Neonatal Outcomes Across Studies 
 Moore et al8 Short et al12 Anaraki et al11 
Gaba Placebo Gaba  
300mg 
Gaba  
600mg 
Placebo Gaba Placebo 
N 21 23 42 42 42 38 39 
Weight (g)a 3520 3341 3429 3505 3382 -- -- 
1-minute Apgarb 9 9 9 9 9 10 10 
5-minute Apgarb 9 9 9 9 9 10 10 
Umbilical artery 
pHa 
7.26 7.29 7.29 7.28 7.28 -- -- 
NICU admissionc 1 0 2 1 2 -- -- 
a – Mean (SD)  b – Median (range) c – Count  
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